Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence

Basel, October 23, 2026 – Novartis today announced results from the six-year follow-up analysis of the Phase III NATALEE trial, reporting positive, clinically meaningful overall survival (OS) data with Kisqali® (ribociclib) plus endocrine therapy (ET) compared to ET alone1. The study was in the broadest early breast cancer (eBC) population of patients with stage II and III HR+/HER2- early breast cancer at high risk of recurrence, including those with high-risk node-negative (N0) disease and all node-positive patients1,2. Kisqali plus ET reduced the risk of death by nearly 20% (19.1%) compared to ET alone (HR=0.809; 95% CI: 0.661-0.989), with consistent overall survival benefit observed across all key subgroups1. These late-breaking results will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2026.